Contents 3 min read
Claim and source comparison
Comparison scope: PubMed abstracts of Llewellyn 2010, VITAL-DEP 2020 and VITAL cognition 2021; NIH ODS sections on metabolites, testing, intake and safety. Not full-text or independent clinical review of all sources.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human observational study
Llewellyn 2010: In 858 adults aged 65+, low 25(OH)D was associated with cognitive decline over six years. Adjusted relative risk for MMSE decline comparing <25 with ≥75 nmol/L was 1.60 (95% CI 1.19–2.00).
An observational cohort is not a supplementation trial; it proves neither causality nor dementia prevention with D3. Comparison thresholds are not universal clinical targets.
Source 4 · Abstract read
Human randomized controlled trial
VITAL-DEP 2020: In 18,353 adults without clinically relevant depressive symptoms at baseline, 2000 IU/day D3 did not significantly reduce depression/relevant symptom risk versus placebo over a median 5.3 years: HR 0.97 (95% CI 0.87–1.09). Mood scores also showed no benefit.
A prevention trial does not test active depression treatment or selected severe-deficiency patients. Its dose is not a personal prescription; associations do not establish preventive benefit.
Source 7 · Abstract read
Human randomized controlled trial
VITAL 2021: 3424 adults aged 60+ were assessed by phone and 794 in person. D3 2000 IU/day did not significantly slow global cognitive decline over 2–3 years: annual difference 0.01 (95% CI −0.01–0.02; p=0.39).
A subgroup signal among Black participants needs confirmation and is distinct from the overall null finding. Limited follow-up does not definitively assess every deficiency group or lifetime dementia risk.
Source 8 · Abstract read
Official safety summary
NIH ODS reports a circulating half-life of about 15 days for 25(OH)D, a D3 metabolite and status marker. Circulating calcitriol has a half-life measured in hours.
Metabolite duration does not define a one-compartment oral D3 decay curve or personal redosing time. The valid 15-day information is retained without a D3 elimination model.
Source 5 · Official summary read
Official safety summary
NIH ODS notes that excessive vitamin D can cause hypercalcemia and kidney damage; thiazides may increase hypercalcemia risk. Routine 25(OH)D testing is not recommended for all healthy people; testing and deficiency treatment depend on clinical context. Do not independently change treatment.
Total daily intake, upper limit and deficiency treatment are distinct concepts. Official guidance is not a personal dose or screening plan; missing interaction records are not safety evidence.
Source 5 · Official summary read
Correction 2026-11-11: Associations were separated from prevention evidence, metabolite duration from D3 elimination. Universal testing instructions and mechanism-based benefit inferences were removed.
What is Vitamin D3?
Vitamin D3 is important for bone and calcium metabolism; treating deficiency depends on medical assessment. Associations of low levels with depression or cognitive decline do not establish that supplements prevent or treat these conditions.
Vitamin D3 (cholecalciferol) is a fat-soluble vitamin synthesized when UVB radiation in sunlight converts skin cholesterol. It is converted to 25-hydroxyvitamin D3 (25-OH-D3) in the liver and then to the active form 1,25-dihydroxyvitamin D3 (calcitriol) in the kidney. Calcitriol in the cell nucleus Vitamin D receptors (VDR) binds and regulates gene expression.
Clinical Trials
Llewellyn 2010: In 858 adults aged 65+, low 25(OH)D was associated with cognitive decline over six years. Adjusted relative risk for MMSE decline comparing <25 with ≥75 nmol/L was 1.60 (95% CI 1.19–2.00).
An observational cohort is not a supplementation trial; it proves neither causality nor dementia prevention with D3. Comparison thresholds are not universal clinical targets.
VITAL-DEP 2020: In 18,353 adults without clinically relevant depressive symptoms at baseline, 2000 IU/day D3 did not significantly reduce depression/relevant symptom risk versus placebo over a median 5.3 years: HR 0.97 (95% CI 0.87–1.09). Mood scores also showed no benefit.
A prevention trial does not test active depression treatment or selected severe-deficiency patients. Its dose is not a personal prescription; associations do not establish preventive benefit.
VITAL 2021: 3424 adults aged 60+ were assessed by phone and 794 in person. D3 2000 IU/day did not significantly slow global cognitive decline over 2–3 years: annual difference 0.01 (95% CI −0.01–0.02; p=0.39).
A subgroup signal among Black participants needs confirmation and is distinct from the overall null finding. Limited follow-up does not definitively assess every deficiency group or lifetime dementia risk.
Dose information and research limits
⚠ Research Limitations
Under NIH/FNB criteria, 25(OH)D ≥50 nmol/L is adequate for most people; 50–75 nmol/L is not a universal deficiency range. Recommended total adult intake is 600 IU/day, or 800 IU above age 70; 4000 IU/day is an upper limit, not a target. Deficiency treatment and testing need individualized assessment.
NIH ODS reports a circulating half-life of about 15 days for 25(OH)D, a D3 metabolite and status marker. Circulating calcitriol has a half-life measured in hours.
Metabolite duration does not define a one-compartment oral D3 decay curve or personal redosing time. The valid 15-day information is retained without a D3 elimination model.
Safety and Side Effects
NIH ODS notes that excessive vitamin D can cause hypercalcemia and kidney damage; thiazides may increase hypercalcemia risk. Routine 25(OH)D testing is not recommended for all healthy people; testing and deficiency treatment depend on clinical context. Do not independently change treatment.
Total daily intake, upper limit and deficiency treatment are distinct concepts. Official guidance is not a personal dose or screening plan; missing interaction records are not safety evidence.
K2 has not been established as mandatory with D3 for everyone or as prevention of vitamin D toxicity. Excess D3 can cause hypercalcemia and kidney injury; adding K2 does not make an overdose safe. Vitamin K can alter warfarin’s effect.
Vitamin D Deficiency in Türkiye
Vitamin D levels in Türkiye vary by age, region, season and study sample. A deficiency percentage from a clinical sample cannot be generalized to the population; a universal claim above 70% is not established.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Vitamins, Minerals and the Brain: Deficiency and Supplement Evidence
Vitamin D, B12, magnesium and zinc deficiencies need assessment; supplements have not been shown to improve cognition in everyone without a deficiency.
Sources
- Holick MF. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281. PubMed · PMID 17634462
- Shaffer JA, et al. (2014). Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine, 76(3), 190–196. PubMed · PMID 24632894
- Eyles DW, et al. (2013). Vitamin D effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Frontiers in Neuroendocrinology, 34(1), 47–64. PubMed · PMID 22796576
- Llewellyn DJ, et al. (2010). Vitamin D and risk of cognitive decline in elderly persons. Archives of Internal Medicine, 170(13), 1135–1141. PubMed · PMID 20625021
- NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ NIH Office of Dietary Supplements
- NIH Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/ NIH Office of Dietary Supplements
- Okereke OI, et al. (2020). Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA, 324(5), 471-480. https://doi.org/10.1001/jama.2020.10224 PubMed · PMID 32749491
- Kang JH, et al. (2021). Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. Scientific reports, 11(1), 23253. https://doi.org/10.1038/s41598-021-02485-8 PubMed · PMID 34853363
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Vitamin D3 is important for bone and calcium metabolism; treating deficiency depends on medical assessment. Associations of low levels with depression or cognitive decline do not establish that supplements prevent or treat these conditions.
Under NIH/FNB criteria, 25(OH)D ≥50 nmol/L is adequate for most people; 50–75 nmol/L is not a universal deficiency range. Recommended total adult intake is 600 IU/day, or 800 IU above age 70; 4000 IU/day is an upper limit, not a target. Deficiency treatment and testing need individualized assessment.
K2 has not been established as mandatory with D3 for everyone or as prevention of vitamin D toxicity. Excess D3 can cause hypercalcemia and kidney injury; adding K2 does not make an overdose safe. Vitamin K can alter warfarin’s effect.
Vitamin D levels in Türkiye vary by age, region, season and study sample. A deficiency percentage from a clinical sample cannot be generalized to the population; a universal claim above 70% is not established.